RxDoctor Payments Data

Joya Ganguly, MD

Clinical Cardiac Electrophysiology · Detroit, MINPI 1043473382

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (36.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 42.7% of the total. Reporting peaked in 2022 at $21,099 and has fallen 76.9% since, to $4,877 in 2025.

$95,795in general payments, 2019–2025

Across 846 payments — averaging $113.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$41K
  • Abbott$30K
  • Medtronic$11K
  • Boston Scientific$5K
  • Medical Device Business Services, Inc.$2K
  • Atricure, Inc.$2K
  • plus $5K from 35 others

What the payments were for

  • Speaking & faculty fees$35,25037%
  • Travel & lodging$25,03126%
  • Food & beverage$35,19637%
  • Education$3180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,795 in reported general payments places this provider in the 85th percentile of 105 clinical cardiac electrophysiology providers in Michigan.

See all clinical cardiac electrophysiology providers in Michigan

Medicare billing

Part B allowed, 2024
$175,994
Medicare patients
861
Services billed
3,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$65,472
XareltoRivaroxaban16$18,002
Metoprolol Succinate76$1,891
Flecainide Acetate22$1,153
Propranolol Hcl ErPropranolol Hcl15$770
Amiodarone Hcl26$488
Metoprolol Tartrate49$458
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$348
Sucralfate12$160
Carvedilol12$156
Amlodipine Besylate16$65
Levofloxacin16$43
Furosemide17$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$289$65,47273 claims
Johnson & JohnsonXarelto$675$18,00216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 105 clinical cardiac electrophysiology providers in Michigan.

Other clinical cardiac electrophysiology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →